Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605769 | 0.85 | MAOB (0.56) | SMN1; SMN2HSP90AA1ALDH1A1NPC1RAB9A | |
| SCHEMBL977997 | 0.84 | HSP90AA1 (0.63) | SMN1; SMN2HSP90AA1ALDH1A1NPC1POLB | |
| SCHEMBL19033787 | 0.84 | HSP90AA1 (0.63) | SMN1; SMN2HSP90AA1ALDH1A1NPC1POLB | |
| SCHEMBL20677772 | 0.82 | HSP90AA1 (0.58) | HSP90AA1ALDH1A1NPC1RAB9ASRD5A2 | |
| SCHEMBL16126217 | 0.81 | HSP90AA1 (0.46) | HSP90AA1 | |
| SCHEMBL18127061 | 0.81 | HSP90AA1 (0.46) | HSP90AA1NPC1RAB9APARP10 | |
| SCHEMBL20677796 | 0.81 | HSP90AA1 (0.56) | SMN1; SMN2HSP90AA1ALDH1A1NPC1POLB | |
| SCHEMBL3923560 | 0.79 | HSP90AA1 (0.54) | HSP90AA1ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL9539946 | 0.79 | HSP90AA1 (0.54) | SMN1; SMN2HSP90AA1ALDH1A1POLBSRD5A2 | |
| SCHEMBL3694184 | 0.79 | HSP90AA1 (0.54) | SMN1; SMN2HSP90AA1ALDH1A1NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| WO-2017134555-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | IDO1, IDO2, TDO2 | SMN1; SMN2 4672/4885HSP90AA1 3424/4885ALDH1A1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.